Clinical Trials Logo

High Grade Serous Ovarian Cancer clinical trials

View clinical trials related to High Grade Serous Ovarian Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05188781 Completed - Clinical trials for High-Grade Serous Ovarian Cancer

Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer

Start date: January 4, 2019
Phase:
Study type: Observational

Primary: To evaluate improvement in progression-free survival for patients treated with anti-PD1 pembrolizumab in combination with Anlotinib as compared to pembrolizumab single treated Secondary: To obtain pilot data on clinical response rates using both RECIST1.1 criteria (Response Evaluation Criteria in Solid Tumors) and immune related response criteria (irRECIST). Objectives • To obtain data on changes in tumor microenvironment prior to and subsequent to therapy and, to screen for potential biomarkers to predict clinical benefit combination in the study population. - To assess the impact of the combination of anlotinib and pembrolizumab - To determine the safety and tolerability of the treatment of anlotinib and pembrolizumab - To evaluate overall survival in patients treated with anti-PD-1 pembrolizumab and anlotinib

NCT ID: NCT03268382 Completed - Clinical trials for High-grade Serous Ovarian Cancer

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

Start date: July 31, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and PLD chemotherapy regimen in patients with platinum-resistant recurrent high grade serous ovarian cancer (HGSOC) with mutated TP53. In addition, the study aims to assess the safety profile of the combined APR-246 and PLD chemotherapy regimen, to evaluate potential biomarkers, and to assess the biological activity in tumor and surrogate tissues. The trial will enroll at least 25 evaluable patients.

NCT ID: NCT02307240 Completed - Solid Tumors Clinical Trials

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

Start date: November 2014
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, multi-center trial designed to evaluate the safety, tolerability and pharmacokinetics of CUDC-907 administered orally to subjects with advanced/relapsed solid tumors.

NCT ID: NCT01853306 Completed - Oncology Clinical Trials

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

Start date: March 18, 2013
Phase: Phase 1
Study type: Interventional

This is a 3 part phase 1 study to evaluate the safety, pharmacokinetic and oral bioavailability of veliparib in subjects with solid tumors.